| [1] |
World Health Organization . Global tuberculosis report 2017. Geneva:World Health Organization, 2017.
|
| [2] |
Royce S, Falzon D, van Weezenbeek C , et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis, 2013,17(4):511-513.
doi: 10.5588/ijtld.12.0286
URL
pmid: 23485384
|
| [3] |
陈明亭, 李仁忠, 阮云洲 , 等. 全球基金耐多药结核病控制项目在中国——成就与经验.北京: 人民卫生出版社, 2015: 1-5.
|
| [4] |
Kim SJ . Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J, 2005,25(3):564-569.
doi: 10.1183/09031936.05.00111304
URL
pmid: 15738303
|
| [5] |
Kim SJ, Espinal MA, Abe C , et al. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis, 2004,8(9):1157-1158.
doi: 10.1016/j.hrtlng.2004.05.003
URL
pmid: 15455606
|
| [6] |
Van Deun A, Martin A, Palomino JC . Diagnosis of drug-resistant tuberculosis:reliability and rapidity of detection. Int J Tuberc Lung Dis, 2010,14(2):131-140.
doi: 10.1016/0040-6031(93)80397-S
URL
pmid: 20074402
|
| [7] |
Richter E, Rüsch-Gerdes S, Hillemann D . Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Respir Med, 2009,3(5):497-510.
doi: 10.1586/ers.09.45
URL
pmid: 20477339
|
| [8] |
World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014.
|
| [9] |
Caminero JA, World Health Organization, American Thoracic Society , et al. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis, 2006,10(8):829-837.
|
| [10] |
李仁忠, 王黎霞 . 实验室新技术用于耐药结核病诊断流程的建议. 中华结核和呼吸杂志, 2016,39(7):568-569.
doi: 10.3760/cma.j.issn.1001-0939.2016.07.020
URL
|
| [11] |
吴哲渊, 张青, 张祖荣 , 等. 上海市耐多药肺结核防治管理模式效果评价. 中国防痨杂志, 2015,37(11):1118-1125.
doi: 10.3969/j.issn.1000-6621.2015.11.008
URL
|
| [12] |
王宇 . 耐多药肺结核防治管理工作方案.北京: 军事医学科学出版社, 2012.
|
| [13] |
World Health Organization . Rapid Implementation of the Xpert MTB/RIF diagnostic test technical and operational ‘How-to’ practical considerations. Geneva:World Health Organization, 2011.
|
| [14] |
Global Laboratory Initiative . GLI model TB diagnostic algorithms. Geneva:Global Laboratory Initiative, 2017.
|
| [15] |
Shah NS, Grace Lin SY, Barry PM , et al. Clinical impact on tuberculosis treatment outcomes of discordance between molecular and growth-based assays for rifampin resistance, California 2003—2013. Open Forum Infect Dis, 2016,3(3):ofw150.
doi: 10.1093/ofid/ofw150
URL
|
| [16] |
Jo KW, Lee S, Kang MR , et al. Frequency and type of disputed rpoB mutations in Mycobacterium tuberculosis isolates from South Korea. Tuberc Respir Dis(Seoul), 2017,80(3):270-276.
doi: 10.4046/trd.2017.80.3.270
URL
|
| [17] |
Pang Y, Ruan YZ, Zhao J , et al. Diagnostic dilemma: treatment outcomes of tuberculosis patients with inconsistent rifam-picin susceptibility. Int J Tuberc Lung Dis, 2014,18(3):357-362.
doi: 10.5588/ijtld.13.0459
URL
|
| [18] |
World Health Organization . Molecular line probe assays for rapid screening of patients screening of patients at risk of multi-drug resistant tuberculosis. Geneva: World Health Organization, 2008.
|
| [19] |
World Health Organization . Rapid implementation of the Xpert MTB/RIF diagnostic test. Geneva: World Health Organization, 2011.
|
| [20] |
World Health Organization . Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifa-mpicin resistance in adults and children. Geneva: World Health Organization, 2013.
|
| [21] |
Van Deun A, Wright A, Zignol M , et al. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis, 2011,15(1):116-124.
|
| [22] |
Xu L, Chen J, Innes AL , et al. Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit. PLoS One, 2017,12(10):e0187076.
doi: 10.1371/journal.pone.0187076
URL
pmid: 5663430
|
| [23] |
Heldal E, Arnadottir T, Cruz JR , et al. Low failure rate in standardized retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of ‘chronic’ patients. Int J Tuberc Lung Dis, 2001,5(2):129-136.
|
| [24] |
Menzies D, Benedetti A, Paydar A , et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med, 2009,6(9):e1000146.
doi: 10.1371/journal.pmed.1000146
URL
|
| [25] |
Caminero Luna JA . A tuberculosis guide for specialist physicians. Paris: International Union Against Tuberculosis and Lung Diseases, 2004.
|
| [26] |
Caminero J . Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis, 2008,12(8):869-877.
|
| [27] |
Williams H, Prokopowicz J . Evaluation of dipasic in treating chronic pulmonary tuberculosis. Tubercle, 1958,39(4):201-205.
doi: 10.1016/S0041-3879(58)80068-9
URL
pmid: 13581191
|
| [28] |
许学受, 许申 . 结核清的综述. 临床肺科杂志, 1997,( 2):1-6.
|
| [29] |
World Health Organization . Treatment guidelines for drug-resistant tuberculosis 2016 update. Geneva: World Health Organization, 2016.
URL
pmid: 27748093
|
| [30] |
Ahuja SD, Ashkin D, Avendano M , et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes:an individual patient data meta-analysis of 9153 patients. PLoS Med, 2012,9(8):e1001300.
doi: 10.1371/journal.pmed.1001300
URL
|
| [31] |
Falzon D, Gandhi N, Migliori GB , et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J, 2013,42(1):156-168.
doi: 10.1183/09031936.00134712
URL
|
| [32] |
Van Deun A, Maug AK, Salim MA , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010,182(5):684-692.
doi: 10.1164/rccm.201001-0077OC
URL
|
| [33] |
代晓琦, 阮云洲, 李仁忠 , 等. “医防合作”模式下实施DOT对耐多药肺结核患者不同治疗转归的分析. 中国防痨杂志, 2016,38(11):929-933.
doi: 10.3969/j.issn.1000-6621.2016.11.008
URL
|
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
